Hosted on MSN10mon
AstraZeneca follows rival, will cap inhaler prices at $35 per month amid scrutiny
(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s ...
pharmaphorum3d
Smart sensor cleared for use with AZ asthma, COPD inhalers
A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers. Developed by Australian medtech firm ...
standardmedia.co.ke4mon
Inhalers: Lifesavers for asthma, but hidden environmental threat
AstraZeneca recently announced the completion of clinical studies for a next-generation propellant (NGP) version of its chronic obstructive pulmonary disease (COPD) inhaler, Breztri. This new ...
The Financial Express15d
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
With the US capping inhaler prices at $35 ... “With Fasenra and Breztri, AstraZeneca is well-positioned to dominate the evolving COPD market. GlobalData projects that, if approved, Fasenra ...